Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference

Rhea-AI Summary

Jazz Pharmaceuticals has announced its participation in the upcoming BofA Securities 2025 Healthcare Conference. The company's management will engage in a fireside chat scheduled for May 14, 2025, at 10:00 a.m. PT / 1:00 p.m. ET / 6:00 p.m. IST.

The event will be accessible via audio webcast through the Investors section of Jazz Pharmaceuticals' website, with a 30-day replay available. Jazz Pharmaceuticals, listed on Nasdaq as JAZZ, is a global biopharma company focused on developing life-changing medicines for patients with serious diseases, particularly in areas with limited treatment options.

The company maintains a diverse portfolio including:

• Leading therapies for sleep disorders and epilepsy
• Growing portfolio of cancer treatments
• Innovative pipeline in oncology and neuroscience

Headquartered in Dublin, Ireland, Jazz operates research and development laboratories and manufacturing facilities across multiple countries.

Positive

• Diversified portfolio including leading therapies in sleep disorders and epilepsy
• Growing portfolio of cancer treatments
• Global presence with R&D labs and manufacturing facilities in multiple countries
• Active pipeline in oncology and neuroscience development

Negative

• None.

DUBLIN, April 30, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the BofA Securities 2025 Healthcare Conference. Company management will participate in a fireside chat on Wednesday, May 14, 2025, at 10:00 a.m. PT / 1:00 p.m. ET / 6:00 p.m. IST.

An audio webcast of the fireside chat will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. A replay of the webcast will be archived on the website for 30 days.

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.

Contacts:
Investors: 
Jeff Macdonald
Executive Director, Investor Relations
Jazz Pharmaceuticals plc
InvestorInfo@jazzpharma.com
Ireland +353 1 634 3211
U.S. +1 650 496 2717

Media:
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
Ireland +353 1 637 2141
U.S. +1 215 867 4948

View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-participate-in-the-bofa-securities-2025-healthcare-conference-302442981.html

SOURCE Jazz Pharmaceuticals plc

FAQ

When is Jazz Pharmaceuticals (JAZZ) presenting at the BofA Securities Healthcare Conference 2025?

Jazz Pharmaceuticals will participate in a fireside chat on Wednesday, May 14, 2025, at 10:00 a.m. PT / 1:00 p.m. ET / 6:00 p.m. IST.

How can investors watch Jazz Pharmaceuticals' (JAZZ) BofA Securities conference presentation?

Investors can access the audio webcast through the Investors section of Jazz Pharmaceuticals' website at investor.jazzpharma.com/investors/events-presentations. A replay will be available for 30 days.

What therapeutic areas does Jazz Pharmaceuticals (JAZZ) focus on in 2025?

Jazz Pharmaceuticals focuses on sleep disorders and epilepsy treatments, with a growing portfolio of cancer treatments. They also have an innovative pipeline in oncology and neuroscience.

Where is Jazz Pharmaceuticals (JAZZ) headquartered and what markets do they serve?

Jazz Pharmaceuticals is headquartered in Dublin, Ireland, with research and development laboratories and manufacturing facilities across multiple countries, serving patients worldwide.

How can investors contact Jazz Pharmaceuticals (JAZZ) investor relations?

Investors can contact Jeff Macdonald, Executive Director of Investor Relations, at InvestorInfo@jazzpharma.com, or call Ireland (+353 1 634 3211) or U.S. (+1 650 496 2717).